Nuvalent Inc (NASDAQ:NUVL) — Market Cap & Net Worth
Market Cap & Net Worth: Nuvalent Inc (NUVL)
Nuvalent Inc (NASDAQ:NUVL) has a market capitalization of $9.12 Billion ($9.12 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2391 globally and #875 in its home market, demonstrating a 0.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nuvalent Inc's stock price $123.96 by its total outstanding shares 73562661 (73.56 Million). Also see Nuvalent Inc asset portfolio for a full breakdown of the balance sheet.
Nuvalent Inc Market Cap History: 2021 to 2026
Nuvalent Inc's market capitalization history from 2021 to 2026. Data shows growth from $1.40 Billion to $9.12 Billion (46.23% CAGR). Also see NUVL cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Nuvalent Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.34% | #52 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.02% | #272 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.49% | #35 of 263 |
Weight: Nuvalent Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nuvalent Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nuvalent Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check NUVL share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NUVL by Market Capitalization
Companies near Nuvalent Inc in the global market cap rankings as of September 18, 2026. Review Nuvalent Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nuvalent Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Nuvalent Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Nuvalent Inc's market cap moved from $1.40 Billion to $ 9.12 Billion, with a yearly change of 46.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.12 Billion | +23.23% |
| 2025 | $7.40 Billion | +28.50% |
| 2024 | $5.76 Billion | +6.37% |
| 2023 | $5.41 Billion | +147.11% |
| 2022 | $2.19 Billion | +56.41% |
| 2021 | $1.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Nuvalent Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.12 Billion USD |
| MoneyControl | $9.12 Billion USD |
| MarketWatch | $9.12 Billion USD |
| marketcap.company | $9.12 Billion USD |
| Reuters | $9.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine k… Read more